1	Evolving Virulence? Decreasing COVID-19 Complications among Massachusetts
2	Healthcare Workers: A Cohort Study
3	Running title: COVID-19 Complications Decreasing among HCWs
4	
5	Authors: Fan-Yun Lan, Robert Filler, Soni Mathew, Eirini Iliaki, Rebecca Osgood, Lou
6	Ann Bruno-Murtha, Stefanos N. Kales
7	
8	Author affiliations: Harvard University T.H. Chan School of Public Health, Boston,
9	Massachusetts, USA (F-Y Lan, R. Filler, S.N. Kales); National Cheng Kung University
10	Hospital, Tainan, Taiwan (F-Y Lan); Cambridge Health Alliance, Harvard Medical
11	School, Cambridge, Massachusetts, USA (S. Mathew, E. Iliaki, R. Osgood, L.A.
12	Bruno-Murtha, S.N. Kales)
13	
14	Corresponding author: Stefanos N. Kales, MD, MPH
15	Occupational Medicine, Cambridge Health Alliance, Macht Building 427
16	1493 Cambridge Street, Cambridge, MA 02139
17	Tel. 617/665-1580 Fax. 617/665-1672
18	E-mail: skales@hsph.harvard.edu

The hypothesis of attenuating SARS-CoV-2 virulence has been raised. We examined
the temporal distribution of COVID-19 complications (ER visits, hospitalization,
intubation/code, and/or death) among healthcare workers in one system that applied
uniform screening criteria throughout the research period, and found the complication
rate significantly decreased after April 15, 2020.

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

Text—word count: 797 (not including Acknowledgments and the author's biographical sketch) There is limited research investigating possible changes in SARS-CoV-2 virulence. Existing evidence shows a decreasing case-fatality rate in the United States (1). However, in relation to virulence, this statistic may be biased by improved clinical acumen as well as increased testing detecting more asymptomatic and paucisymptomatic cases. An Italian study has demonstrated lower nasopharyngeal viral load in the later phase of the pandemic (2). In addition, attenuated SARS-CoV-2 variants have been reported (3,4). Therefore, we investigated the temporal distribution of COVID-19 complications among healthcare workers (HCWs) to determine if the clinical case severity decreased over time. This retrospective cohort study examined adult HCWs from a Massachusetts community healthcare system using a uniform COVID-19 protocol to screen and test employees since the initial outbreak in March 2020. Inclusion criteria were: 1) COVID-19 triage via the occupational health "hotline" and a documentation of a positive SARS-CoV-2 viral assay between March 9 and July 8, 2020, or 2) any untriaged employee with a complication due to COVID-19 subsequently confirmed by

the system's occupational health department. Since the initial outbreak, the

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

occupational health "hotline" phone-interviewed HCWs with any concerns regarding a) travel; b) potential contact with a COVID-19-positive/suspect person; or c) possible viral symptoms, and referred HCWs for a nasopharyngeal SARS-CoV-2 RT-PCR assay when clinically indicated. HCWs tested outside the system sent in their PCR results for confirmation. All cases were contacted regularly and followed until July 31, 2020 for any complication, including: ER (Emergency Room) visit, hospitalization, intubation/code, and/or death. Detailed data acquisition, de-identification and ethical statement have been published previously (5). Because Massachusetts has used April 15th as the date to measure improvements from the states' pandemic peak (Figure) (6), we defined the cases triaged up to April 15, 2020, as "early", and those afterwards as "late". We also included as early, any untriaged death occurring within 18 days of April 15, 2020 based on the median time from infection onset to death (7,8). Sensitivity analysis was done by restricting the study population to only triaged COVID-19 cases. We used the t-test or Wilcoxon rank sum test, as appropriate, to compare continuous variables, and chi-square test or the Fisher's exact test, as appropriate, for categorical variables. Logistic regression models were built for multivariate adjustment. The analyses were performed using R software (version 3.6.3), two-sided and with a

P-value < 0.05 considered statistically significant.

64 The temporal distribution of incident COVID-19 cases in the study population 65 showed a pattern similar to that statewide (6) (Figure). A total of 166 eligible cases were 66 identified in the study period: 98 early and 68 late. There were no significant 67 differences between early and late cases regarding age, sex, race, residential 68 community attack rates (6), and number of presenting symptoms. Cough was more 69 frequently reported in early cases (66% vs. 50%, P=0.04), while headache was more 70 frequently reported later (42% vs. 60%, P=0.03). There were a total of 13 cases with 71 any complications in the database, comprised of 12 early cases and one late case 72 (P=0.02). Ten cases experienced hospitalization or death (9 early vs. 1 late, P<0.05). 73 Three cases underwent intubation or a code (all early cases) and two of these HCWs 74 died (Table). After adjusting for age, sex, and race, early cases had increased odds 75 ratios (ORs) in any complication(s) (10.3, 95%CI: 1.7-199.9), and 76 hospitalization/death (6.2, 95%CI: 1.0-122.5). 77 In the sensitivity analysis, we excluded one COVID-19 death on April 29, who did 78 not undergo triage and had an unknown date of symptom onset. The results remained 79 significant regarding early versus late total complications: 11.3% (11/97) and 1.5% 80 (1/68) (P=0.02).

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

Our study provides epidemiologic support for the hypothesis of possible attenuated viral virulence (2-4) regarding clinical severity. We found cases infected later in the pandemic were less likely to sustain a complication. Later cases were also more likely to have headache, which may portend a more favorable course (9). The current study has several strengths. First, we used uniform screening protocols and testing criteria for all employees throughout the study period, minimizing bias from younger and less symptomatic cases detected as testing became more widespread. In fact, we observed that the age, sociodemographic characteristics and presenting symptoms of early and late cases were in fact quite similar, and the results remained significant after adjusting for these potential confounders. Second, the similar temporal epidemic pattern between the HCWs and the general population implies possible generalizability to other working populations. Nonetheless, the present study had limited sample size and HCWs' underlying medical conditions were unavailable. Additional investigations are warranted in larger populations with adjustment for underlying comorbidities, other factors predisposing to complications and clinical management. Second, although our results implied headache may be associated with more favorable outcomes, we cannot exclude the possibility that headache is more likely to be perceived by patients with mild illness.

Dr. Lan is a PhD candidate in Population Health Sciences at Harvard University,

USA. He is also an occupational physician at National Cheng Kung University

Hospital, Taiwan. His primary research interest involves environmental and

occupational medicine and epidemiology.

Acknowledgments

All authors declare no competing interest, and none of the authors receives

funding toward the present study.

107 References 108 1. Our World in Data. Statistics and research: mortality risk of COVID-19. [cited 109 2020 Aug 16]. 110 https://ourworldindata.org/mortality-risk-covid#how-did-confirmed-deaths-an 111 d-cases-change-over-time 112 2. Clementi N, Ferrarese R, Tonelli M, Amato V, Racca S, Locatelli M, et al. 113 Lower nasopharyngeal viral load during the latest phase of COVID-19 114 pandemic in a Northern Italy University Hospital. Clin Chem Lab Med. 2020; 115 Epub ahead of print. doi: 10.1515/cclm-2020-0815 116 3. Lau SY, Wang P, Mok BW, Zhang AJ, Chu H, Lee AC, et al. Attenuated 117 SARS-CoV-2 variants with deletions at the S1/S2 junction. Emerg Microbes 118 Infect. 2020;9:837–842. doi:10.1080/22221751.2020.1756700 119 4. Benvenuto D, Angeletti S, Giovanetti M, Bianchi M, Pascarella S, Cauda R, et 120 al. Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural 121 Protein 6 (NSP6) could affect viral autophagy. J Infect. 2020;81:e24–e27. doi: 122 10.1016/j.jinf.2020.03.058 123 5. Lan FY, Filler R, Mathew S, Buley J, Iliaki E, Bruno-Murtha LA, et al. 124 COVID-19 symptoms predictive of healthcare workers' SARS-CoV-2 PCR

125		results. PLoS One. 2020;15:e0235460. doi:10.1371/journal.pone.0235460
126	6.	Massachusetts Department of Public Health. COVID-19 response reporting.
127		[cited 2020 Aug 16].
128		https://www.mass.gov/info-details/covid-19-response-reporting
129	7.	Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of
130		critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a
131		single-centered, retrospective, observational study. Lancet Respir Med.
132		2020;8:475–481. doi:10.1016/S2213-2600(20)30079-5
133	8.	Wilson N, Kvalsvig A, Barnard LT, Baker MG. Case-Fatality risk estimates for
134		COVID-19 calculated by using a lag time for fatality. Emerg Infect Dis.
135		2020;26:1339–1441. doi: 10.3201/eid2606.200320
136	9.	Greb E. Headache may predict clinical evolution of COVID-19. Neurology
137		Reviews [Internet]. 2020 Jun [cited 2020 Aug 16].
138		https://www.mdedge.com/neurology/article/224253/headache-migraine/heada
139		che-may-predict-clinical-evolution-covid-19
140		
141		

142 Table. Early and late COVID-19 cases' clinical characteristics and complication rates

	Early (thru 15 April) (n=98)	Late (16 April–9 July) (n=68)	P-value
Age (n=166)	43.1 (12.9)	41.5 (11.9)	0.440
Sex (n=159)	10.1 (12.0)	11.5 (11.5)	0.944
Female	70 (71.4%)	46 (67.6%)	0.011
Male	25 (25.5%)	18 (26.5%)	
Race (n=156)	20 (20.070)	. (20.070)	0.517
Non-Hispanic white	38 (38.8%)	18 (26.5%)	0.0
African American	33 (33.7%)	27 (39.7%)	
Hispanic	18 (18.4%)	14 (20.6%)	
Others	5 (5.1%)	3 (4.4%)	
Cumulative community attack	- (- ', ')	- \	
rate*	1723.7 (1214.2-3393.3)	1802.8 (1634.5-2330.2)	0.883†
(as of June 3) (n=156)	,	,	
Total number of symptoms	4 (3–5)	4 (2–5)	0.529†
(n=165)	,	` '	·
No symptom	4 (4.1%)	4 (5.9%)	0.718‡
Fever	50 (51.0%)	25 (36.8%)	0.086
Cough	65 (66.3%)	34 (50.0%)	0.042
Dyspnea	13 (13.3%)	12 (17.6%)	0.598
Myalgia	48 (49.0%)	34 (50.0%)	0.999
Malaise	51 (52.0%)	29 (42.6%)	0.272
Nasal symptoms	33 (33.7%)	28 (41.2%)	0.439
GI symptoms	26 (26.5%)	15 (22.1%)	0.609
Rash	3 (3.1%)	1 (1.5%)	0.644‡
Anosmia/Ageusia	14 (14.3%)	18 (26.5%)	0.085
Headache	41 (41.8%)	41 (60.3%)	0.034
Sore throat	41 (41.8%)	20 (29.4%)	0.129
Any complication(s) (n=166)	12 (12.2%)	1 (1.5%)	0.016‡
ER visit	12 (12.2%)	1 (1.5%)	0.016‡
Hospitalization/death§	9 (9.2%)	1 (1.5%)	0.049‡
Intubation/coded§	3 (3.1%)	0	0.270‡
Death	2 (2.0%)	0	0.513‡

Mean (SD) for age. Median (Q1-Q3) for cumulative community attack rate and total number of symptoms. Count (%)

144 for other variables.

Nasal symptoms include runny, sneezing, congestion, and sinus symptoms. GI (Gastrointestinal) symptoms include

nausea/ vomiting/ diarrhea. ER, Emergency Room.

*Community rates based on Massachusetts data for each healthcare worker's town of residence.

148 †Wilcoxon rank sum test

149 ‡Fisher's exact test

150 §Patient coded and died in an Emergency Department.

145

147

Figure. Temporal Distribution of Incident Confirmed COVID-19 Cases from

March 5 to July 9, 2020 in (A) the Study Population and (B) Massachusetts

Statewide.

Bars indicate the absolute number of daily cases, and the red line denotes the 7-day average of new cases.

